New collaborative research shows that treatment with immune checkpoint inhibitors (ICIs) has led to a significant improvement in survival and response rates among patients with a particularly aggressive type of kidney cancer: advanced sarcomatoid renal cell carcinoma. The study, which was led by a team from Roswell Park Comprehensive Cancer Center and involved contributors from six centers, is detailed in a presentation at the American Society of Clinical Oncology 2021 virtual annual meeting (abstract 4568).
Researchers at Roswell Park Comprehensive Cancer Center led the largest study to date to suggest an improving trend in pathologic complete response rates over time for U.S. cancer patients of various races. The team’s findings, documented in a poster presentation at the 2021 American Society of Clinical Oncology virtual annual meeting (abstract 575), show that African Americans are more likely than patients from any other group to have remaining disease following breast cancer treatment.
New work from a team at Roswell Park Comprehensive Cancer Center will help guide the care of patients with neuroendocrine tumors, or NETs. In a poster presentation at the American Society of Clinical Oncology (ASCO) virtual Annual Meeting 2021, Abhay Singh, MD, MPH, and colleagues outline their discovery of a potential biomarker to predict which patients are likely to experience blood toxicity side effects from a new targeted radiation treatment, peptide receptor radionuclide therapy (PRRT).
Innovative research refines the treatment of patients with advanced cancers and the use of immunotherapy
Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing their DNA (called a PARP inhibitor) has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.
Researchers from the Abramson Cancer Center at the University of Pennsylvania will be presenting data on the latest advances in cancer research and treatment at American Society of Clinical Oncology virtual annual meeting, including new findings on minority health, immunotherapy, and…
Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer research meeting. Moffitt investigators will lead 25 abstract presentations, five education sessions, two cancer-based panels and two clinical science symposia. The virtual meeting is June 4-8.
Atlantic Health System Cancer Care, in partnership with OncLive, invites health care professionals and others interested in the surgical management of melanoma to a virtual lecture by internationally known melanoma expert Charles M. Balch, MD, FACS, FASCO. Dr. Balch is this year’s Joseph Calello Melanoma Scholar. The free lecture and Q & A will be held on May 6, 11 a.m. – 12 p.m. ET.
Rutgers Cancer Institute of New Jersey Associate Chief of Urology and Urologic Oncology and Director of the Kidney Cancer Program Eric A. Singer, MD, MA, MS, FACS, has been named a Fellow of the American Society of Clinical Oncology (FASCO). This distinction honors members for their extraordinary volunteer service and dedication to the American Society of Clinical Oncology (ASCO).
During the peak of the COVID-19 pandemic, several elective surgeries for renal cell carcinoma, the most common type of kidney cancer, were delayed with unknown impact on outcomes for patients. Researchers at Rutgers Cancer Institute of New Jersey explored the impact of surgery delays for these patients throughout the United States by utilizing the National Cancer Database to explore outcomes of patients who underwent surgery up to and after three months post diagnosis.
Dylan Graetz, M.D., M.P.H., a pediatric hematology-oncology fellow at St. Jude, has received a Young Investigator Award from the American Society of Clinical Oncology.
Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan. But a treating professional’s decision to depart from the recommendations of these decision-support resources may be well-founded and in the patient’s best interests, a new Roswell Park study shows.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting, a Roswell Park Comprehensive Cancer Center team reports that in many cases, these newer treatment approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.
By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.
Ronald Chen, MD, MPH, has been named a Fellow of the American Society of Clinical Oncology (FASCO) in honor of his extraordinary volunteer service, dedication and commitment to ASCO.
New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis—published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.